13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001017645
Total reported value
$2.9B
$2.9B
15 檔
97.2%
The Q2 2025 SEC filing reveals that General Atlantic, L.p. held a total portfolio value of $2.9B, covering 15 public equity positions.
General Atlantic, L.p. executed strategic sector rebalancing during Q2 2025, establishing 3 new positions while fully exiting 3 holdings and trimming 2 positions.
In terms of portfolio concentration, the top 5 core holdings (including DLO, CHYM, ALHC) accounted for 97.2% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DLO | DLocal Limited | Stock-Other | 19.97% | -7.31% | — | |
| 2 | CHYM | Chime Financial Inc-cl A | Stock-Other | 18.26% | -3.55% | — | |
| 3 | ALHC | Alignment Healthcare Inc | Stock-Other | 16.97% | — | -27.87% | |
| 4 | XPEV | XPeng Inc. | Stock-Other | 14.20% | -6.73% | -13.84% | |
| 5 | AKRO | Akero Therapeutics Inc | Stock-Other | 8.43% | — | +9.55% | |
| 6 | ALKT | Alkami Technology Inc | Stock-Other | 8.01% | +0.89% | — | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 3.65% | -2.77% | — | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.51% | -2.50% | EXIT | |
| 9 | ✓ | Stock-Other | 2.36% | -0.01% | EXIT | ||
| 10 | EWCZ | European Wax Center Inc-a | Stock-Other | 2.03% | -3.53% | EXIT | |
| 11 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.49% | — | — | |
| 12 | RSKD | Riskified Ltd. | Stock-Other | 0.73% | -0.05% | — | |
| 13 | ADAG | Adagene Inc-adr | Stock-Other | 0.21% | — | — | |
| 14 | ALMS | Alumis Inc | Stock-Other | 0.11% | — | — | |
| 15 | GROV | Grove Collaborative Holdings | Stock-Other | 0.08% | -0.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CHYM | Chime Financial Inc-cl A | +18.3% | NEW | New buy |
| 2 | ✓ | +2.4% | NEW | New buy | |
| 3 | DLO | DLocal Limited | +2.1% | — | Unchanged |
| 4 | AKRO | Akero Therapeutics Inc | +1.3% | +9.55% | Add |
| 5 | XPEV | XPeng Inc. | +0.5% | -13.84% | Trim |
| 6 | EWCZ | European Wax Center Inc-a | +0.3% | — | Unchanged |
| 7 | ALMS | Alumis Inc | +0.1% | NEW | New buy |
| 8 | ADAG | Adagene Inc-adr | 0% | — | Unchanged |
| 9 | GROV | Grove Collaborative Holdings | 0% | — | Unchanged |
| 10 | RPRX | Royalty Pharma plc | -0.1% | — | Unchanged |
| 11 | RSKD | Riskified Ltd. | -0.1% | — | Unchanged |
| 12 | 5ZZ0 | Contextlogic Inc - A | -0.1% | EXIT | Sold out |
| 13 | ✓ | Acelyrin Inc | -0.2% | EXIT | Sold out |
| 14 | PHVS | Pharvaris N.V. | -0.3% | — | Unchanged |
| 15 | ALKT | Alkami Technology Inc | -0.5% | — | Unchanged |
| 16 | 260 | Centessa Pharmaceuticals-adr | -1.2% | — | Unchanged |
| 17 | IMCR | Immunocore Holdings Plc-adr | -1.3% | EXIT | Sold out |
| 18 | ALHC | Alignment Healthcare Inc | -21.2% | -27.87% | Trim |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 15 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CHYM
市值: $662.9M
Top Position Liquidated / Trimmed
IMCR
前期市值: $37.4M
During Q2 2025, General Atlantic, L.p.'s top holdings by market value included DLO (20.0%)、CHYM (18.3%)、ALHC (17.0%). The largest single position, DLO, represented 20.0% of total portfolio value.
In Q2 2025, General Atlantic, L.p. made 9 total portfolio adjustments, initiating 3 new buys, adding to 1 positions, trimming 2 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.